Incidence and survival differences in esophageal cancer among ethnic groups in the United States-Reference-Cited by-同舟云学术

Incidence and survival differences in esophageal cancer among ethnic groups in the United States

Published:2017-03-30 Issue:29 Volume:8 Page:47037-47051
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Chen Zheling¹,Ren Yinghong²,Du Xianglin L.³,Yang Jiao¹,Shen Yanwei¹,Li Shuting¹,Wu Yunying¹,Lv Meng¹,Dong Danfeng¹,Li Enxiao¹,Li Wei⁴,Liu Peijun⁵,Yang Jin¹,Yi Min¹⁶

Affiliation:

1. Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People's Republic of China

2. Department of Internal Medicine, Shangluo Central Hospital, Shangluo, Shaanxi, People's Republic of China

3. Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas School of Public Health, Houston, TX, USA

4. Weapon Industry Health Research Institute, Xian, Shaanxi, People's Republic of China

5. Department of Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People's Republic of China

6. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial, Ethnic, and Sex Differences in Incidence-Based Mortality of Aggregate Upper Gastrointestinal Cancers;Clinical and Translational Gastroenterology;2024-07-15

2. Racial Disparity in Esophageal Squamous Cell Carcinoma Treatment and Survival in the United States;American Journal of Gastroenterology;2023-12-20

3. Epidemiology of Esophageal Squamous Cell Carcinoma;Foregut: The Journal of the American Foregut Society;2023-10-26

4. Global comparative transcriptomes uncover novel and population-specific gene expression in esophageal squamous cell carcinoma;Infectious Agents and Cancer;2023-08-28

5. Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma;Cancer Medicine;2023-07-25